Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1618250
Reference Type
Journal Article
Title
Design and in vivo evaluation of an indapamide transdermal patch
Author(s)
Ren, C; Fang, L; Ling, L; Wang, Q; Liu, S; Zhao, L; He, Z
Year
2009
Is Peer Reviewed?
Yes
Journal
International Journal of Pharmaceutics
ISSN:
0378-5173
EISSN:
1873-3476
Volume
370
Issue
1-2
Page Numbers
129-135
Language
English
PMID
19114099
DOI
10.1016/j.ijpharm.2008.12.004
Abstract
The aim of the present study was to develop and evaluate a novel drug-in-adhesive transdermal patch system for indapamide. Initial in vitro experiments were conducted to optimize formulation parameters prior to transdermal delivery in rats. The effects of the type of adhesive and the content of permeation enhancers on indapamide transport across excised rat skin were evaluated. The results indicated that DURO-TAK adhesive 87-2852 is a suitable and compatible polymer for the development of transdermal drug delivery systems for indapamide. The final formulation contained 4% N-dodecylazepan-2-one, 6% l-menthol and 3% isopropyl myristate. For in vivo studies patch systems were administered transdermally to rats while orally administered indapamide in suspension was used as a control. The PK parameters, such as the maximum blood concentration (C(max)), time to reach the peak blood concentration (T(max)), mean residence time (MRT), area under the curve (AUC(0-t)) and terminal elimination half-life (T(1/2)) were significantly (p<0.05) different following transdermal administration compared with oral administration. In contrast to oral delivery, a sustained activity was observed over a period of 48h after transdermal administration. This sustained activity was due to the controlled release of drug into the systemic circulation following transdermal administration.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity